96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-005629-21-HU
(EUCTR)
14/08/201411/06/2014Diagnostic use of 99mTecnetium labeled infliximab in Crohn’s diseaseDiagnostic use of 99mTecnetium labeled infliximab in Crohn’s disease Crohn’s disease
MedDRA version: 17.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Remicade
Product Name: Infliximab (Remicade): 100 mg of lyophilized infliximab
INN or Proposed INN: INFLIXIMAB
First Department of Medicine, University of SzegedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Hungary
2NCT00207675
(ClinicalTrials.gov)
February 200313/9/2005A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's DiseaseA Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease.Crohn DiseaseDrug: infliximabCentocor, Inc.Centocor BVCompleted6 Years17 YearsBoth112Phase 3NULL
3NCT00261976
(ClinicalTrials.gov)
February 20022/12/2005A Long-term Safety Study of Infliximab (Remicade)Long-term Safety Follow-up of REMICADE (RESULTS)Arthritis, Rheumatoid;Crohn Disease;PsoriasisDrug: Infliximab (Remicade)Centocor, Inc.Centocor BVCompletedN/AN/ABoth2971United States;Argentina;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom
4NCT00207662
(ClinicalTrials.gov)
July 200013/9/2005A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's DiseaseACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's DiseaseCrohn DiseaseDrug: infliximab or placeboCentocor, Inc.NULLCompleted18 YearsN/ABoth580Phase 3NULL
5NCT00207766
(ClinicalTrials.gov)
June 200013/9/2005A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's DiseaseACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S DiseaseCrohn DiseaseDrug: infliximab or placeboCentocor, Inc.NULLCompleted18 YearsN/ABoth306Phase 3NULL